A controlled trial of a human papillomavirus type 16 vaccine

New England Journal of Medicine

Volumn 347, Issue 21, 2002, Pages 1645-1651

  Koutsky, Laura A ^{a,b,c,d,e,f,g}   Ault, Kevin A ^a,b,c,d,e,f   Wheeler, Cosette M ^a,b,c,d,e,f   Brown, Darron R ^a,b,c,d,e,f   Barr, Eliav ^a,b,c,d,e,f   Alvarez, Frances B ^a,b,c,d,e,f   Chiacchierini, Lisa M ^a,b,c,d,e,f   Jansen, Kathrin U ^a,b,c,d,e,f  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^d INDIANA UNIVERSITY   (United States)

^e Biologics Clinical Research   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

^g HPV Research Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS DNA; VIRUS VACCINE; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COLPOSCOPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; INFECTION PREVENTION; INFECTION RATE; INJECTION PAIN; NORMAL HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VIRUS DETECTION; VIRUS INFECTION; VIRUS PARTICLE; VIRUS TYPING; WART VIRUS;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA, VIRAL; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VIRAL VACCINES;

EID: 0037153042     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa020586     Document Type: Article

References (32)

1. Bauer HM, Ting Y, Greer CE, et al. Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA 1991;265:472-7.
2. Ho GYF, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-8.
3. Stone KM, Karem KL, Sternberg MR, et al. Seroprevalence of HPV16 in the United States, 1991-1994. Presented at the 18th International Papillomavirus Conference, Barcelona, Spain, July 23-28, 2000. abstract.
4. Moscicki AB, Hills N, Shiboski S, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 2001;285:2995-3002.
5. LARC Working Group on the Evaluation of Carcinogenic Risks to Humans. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 64. Human Papillomaviruses. Lyons, France: International Agency for Research on Cancer, 1995.
6. Nobbenhnis MA, Walboomers JM, Helmerhorst TJ, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: A prospective study. Lancet 1999;354:20-5.
7. Ho GYF, Burk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995;87:1365-71.
8. Wallin K-L, Wiklund F, Ångström T, et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med 1999;341:1633-8.
9. zur Hausen H. Immortalization of human cells and their malignant conversion by high risk human papillomavirus genotypes. Semin Cancer Biol 1999;9:405-11.
10. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. J Natl Cancer Inst 1995;87:796-802.
11. Kulasingam SL, Hughes JP, Kiviat NB, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: Comparison of sensitivity, specificity, and frequency of referral. JAMA 2002;288:1749-57.
12. The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: Baseline data from a randomized trial. J Natl Cancer Inst 2000;92:397-402.
13. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991;185:251-7
14. Hagensee ME, Yaegashi N, Galloway DA. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpressinn of the L1 and L2 capsid proteins. J Virol 1993;67:315-22.
15. Kirnbauer R, Hubbert NL, Wheeler CM, Becker TM, Lowy DR, Schiller JT. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst 1994;86:494-9.
16. Jansen KU, Rosolowsky M, Schultz LD, et al. Vaccination with yeastexpressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine 1995;13:1509-14.
17. Christensen ND, Kreider JW. Antibody-mediated neutralization in vivo of infectious papillomaviruses. J Virol 1990;64:3151-6.
18. Brown DR, Bryan JT, Schroeder JM, et al. Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: Correlation with competitive radioimmunoassay titer. J Infect Dis 2001;184:1183-6.
19. Suzich JA, Ghim SJ, Palmer-Hill FJ, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A 1995;92:11553-7.
20. Lin YL, Borenstein LA, Ahmed R, Wettstein FO. Cottontail rabbit papillomavirus L1 protein-based vaccines: Protection is achieved only with a full-length, nondenatured product. J Virol 1993;67:4154-62.
21. Harro CD, Pang YY, Roden RB, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001;93:284-92.
22. Poland GA, Hagensee M, Koutsky LA, et al. A randomized, doubleblind, placebo-controlled trial of the immunogenicity and reactogenicity of a novel HPV16 vaccine: Preliminary results. Presented at the 18th International Papillomavirus Conference, Barcelona, Spain, July 23-28, 2000. abstract.
23. Koutsky LA, Miller LR, Poland GA, et al. Persistence of HPV16 antibodies after immunization with HPV16 L1 virus-like particle (VLP) vaccines. Presented at the 19th International Papillomavirus Conference, Florianopolis, Brazil, September 1-7, 2001. abstract.
24. Kurman RJ, Solomon D. The Bethesda System for Reporting Cervical/Vaginal Cytologic Diagnoses: Definitions, Criteria, and Explanatory Notes for Terminology and Specimen Adequacy. New York: Springer-Verlag, 1994.
25. Palker TJ, Monteiro JM, Martin MM, et al. Antibody, cytokine and cytotoxic T lymphocyte responses in chimpanzees immunized with human papillomavirus virus-like particles. Vaccine 2001;19:3733-43.
26. Lowe RS, Brown DR, Bryan JT, et al. Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast. J Infect Dis 1997;176:1141-5.
27. Chan ISF, Bohidar NR. Exact power and sample size for vaccine efficacy studies. Commun Stat Theory Methods 1998;27:1305-22.
28. Cassidy WM, Watson B, Ioli VA, Williams K, Bird S, West DJ. A randomized trial of alternative two- and three-dose hepatitis B vaccination regimens in adolescents: Antibody responses, safety, and immunologic memory. Pediatrics 2001;107:626-31.
29. Liglof T, van Hattum J, Kaplan KM, et al. An open study of subcutaneous administration of inactivated hepatitis A vaccine (VAQTA) in adults: Safety, tolerability, and immunogenicity. Vaccine 2001;19:3968-71. [Erratum, Vaccine 2001;20:281.]
30. Carter JJ, Koutsky LA, Hughes JP, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000;181:1911-9.
31. Wideroff L, Schiffman M, Haderer P, et al. Seroreactivity to human papillomavirus types 16, 18, 31, and 45 virus-like particles in a case-control study of cervical squamous intraepithelial lesions. J Infect Dis 1999;180:1424-8.
32. Thomas KK, Hughes JP, Kuypers JM, et al. Concurrent and sequential acquisition of different genital human papillomavirus types. J Infect Dis 2000;182:1097-102.